154 related articles for article (PubMed ID: 15179321)
41. Treating inflammation with the Janus kinase inhibitor CP-690,550.
Vijayakrishnan L; Venkataramanan R; Gulati P
Trends Pharmacol Sci; 2011 Jan; 32(1):25-34. PubMed ID: 21144599
[TBL] [Abstract][Full Text] [Related]
42. Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket.
Forster M; Chaikuad A; Bauer SM; Holstein J; Robers MB; Corona CR; Gehringer M; Pfaffenrot E; Ghoreschi K; Knapp S; Laufer SA
Cell Chem Biol; 2016 Nov; 23(11):1335-1340. PubMed ID: 27840070
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases.
Muromoto R; Shimoda K; Oritani K; Matsuda T
Biol Pharm Bull; 2021; 44(11):1585-1592. PubMed ID: 34719635
[TBL] [Abstract][Full Text] [Related]
44. JAK3 inhibition as a new concept for immune suppression.
Borie DC; Si MS; Morris RE; Reitz BA; Changelian PS
Curr Opin Investig Drugs; 2003 Nov; 4(11):1297-303. PubMed ID: 14758768
[TBL] [Abstract][Full Text] [Related]
45. Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3.
Säemann MD; Diakos C; Kelemen P; Kriehuber E; Zeyda M; Böhmig GA; Hörl WH; Baumruker T; Zlabinger GJ
Am J Transplant; 2003 Nov; 3(11):1341-9. PubMed ID: 14525593
[TBL] [Abstract][Full Text] [Related]
46. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.
Meyer DM; Jesson MI; Li X; Elrick MM; Funckes-Shippy CL; Warner JD; Gross CJ; Dowty ME; Ramaiah SK; Hirsch JL; Saabye MJ; Barks JL; Kishore N; Morris DL
J Inflamm (Lond); 2010 Aug; 7():41. PubMed ID: 20701804
[TBL] [Abstract][Full Text] [Related]
47. Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases.
Farmer LJ; Ledeboer MW; Hoock T; Arnost MJ; Bethiel RS; Bennani YL; Black JJ; Brummel CL; Chakilam A; Dorsch WA; Fan B; Cochran JE; Halas S; Harrington EM; Hogan JK; Howe D; Huang H; Jacobs DH; Laitinen LM; Liao S; Mahajan S; Marone V; Martinez-Botella G; McCarthy P; Messersmith D; Namchuk M; Oh L; Penney MS; Pierce AC; Raybuck SA; Rugg A; Salituro FG; Saxena K; Shannon D; Shlyakter D; Swenson L; Tian SK; Town C; Wang J; Wang T; Wannamaker MW; Winquist RJ; Zuccola HJ
J Med Chem; 2015 Sep; 58(18):7195-216. PubMed ID: 26230873
[TBL] [Abstract][Full Text] [Related]
48. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3.
Thomis DC; Gurniak CB; Tivol E; Sharpe AH; Berg LJ
Science; 1995 Nov; 270(5237):794-7. PubMed ID: 7481767
[TBL] [Abstract][Full Text] [Related]
49. JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells.
Rane SG; Reddy EP
Oncogene; 1994 Aug; 9(8):2415-23. PubMed ID: 7518579
[TBL] [Abstract][Full Text] [Related]
50. IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling.
Murata T; Noguchi PD; Puri RK
J Immunol; 1996 Apr; 156(8):2972-8. PubMed ID: 8609418
[TBL] [Abstract][Full Text] [Related]
51. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice.
Park SY; Saijo K; Takahashi T; Osawa M; Arase H; Hirayama N; Miyake K; Nakauchi H; Shirasawa T; Saito T
Immunity; 1995 Dec; 3(6):771-82. PubMed ID: 8777722
[TBL] [Abstract][Full Text] [Related]
52. Jak3 activation in human lymphocyte precursor cells.
Sharfe N; Dadi HK; O'Shea JJ; Roifman CM
Clin Exp Immunol; 1997 Jun; 108(3):552-6. PubMed ID: 9182906
[TBL] [Abstract][Full Text] [Related]
53. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants.
Borie DC; O'Shea JJ; Changelian PS
Trends Mol Med; 2004 Nov; 10(11):532-41. PubMed ID: 15519279
[TBL] [Abstract][Full Text] [Related]
54. Janus kinase 3: a novel target for selective transplant immunosupression.
Podder H; Kahan BD
Expert Opin Ther Targets; 2004 Dec; 8(6):613-29. PubMed ID: 15584866
[TBL] [Abstract][Full Text] [Related]
55. Targeting Jak3 for immune suppression and allograft acceptance.
Kirken RA
Transplant Proc; 2001; 33(7-8):3268-70. PubMed ID: 11750399
[No Abstract] [Full Text] [Related]
56. Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting.
Forster M; Gehringer M; Laufer SA
Bioorg Med Chem Lett; 2017 Sep; 27(18):4229-4237. PubMed ID: 28844493
[TBL] [Abstract][Full Text] [Related]
57. [Regulation of inflammation through JAK3-Stat6 pathway in dendritic cells].
Yamaoka K; Maeshima K; Kubo S; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):62-8. PubMed ID: 22374445
[TBL] [Abstract][Full Text] [Related]
58. Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3.
Nakajima Y; Inoue T; Nakai K; Mukoyoshi K; Hamaguchi H; Hatanaka K; Sasaki H; Tanaka A; Takahashi F; Kunikawa S; Usuda H; Moritomo A; Higashi Y; Inami M; Shirakami S
Bioorg Med Chem; 2015 Aug; 23(15):4871-4883. PubMed ID: 26071372
[TBL] [Abstract][Full Text] [Related]
59. Mucosal Epithelial Jak Kinases in Health and Diseases.
Kumar N; Kuang L; Villa R; Kumar P; Mishra J
Mediators Inflamm; 2021; 2021():6618924. PubMed ID: 33814980
[TBL] [Abstract][Full Text] [Related]
60. The specificity of JAK3 kinase inhibitors.
Changelian PS; Moshinsky D; Kuhn CF; Flanagan ME; Munchhof MJ; Harris TM; Whipple DA; Doty JL; Sun J; Kent CR; Magnuson KS; Perregaux DG; Sawyer PS; Kudlacz EM
Blood; 2008 Feb; 111(4):2155-7. PubMed ID: 18094329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
